Stefano Luminari

University of Modena and Reggio Emelia, Italy

ASSOCIATE PROFESSOR MEDICAL ONCOLOGY, University of Modena and Reggio Emilia.
Head of the unit for “Clinical research in oncohematology” at the Hematology Division, AUSL IRCCS Reggio Emilia

Other positions:
• Chair of the “indolent lymphoma” committee of the Fondazione Italiana Linfomi (FIL) (2019 –Ongoing)
• Legal representative for the European Community of the International Extranodal Lymphoma Study Group (IELSG)(2020 – ongoing)
• Associate Editor of Italian edition of “Blood” (2019 – ongoing)

Education, training and work experience
1996 University degree in Medicine “’Università degli Studi di Milano” Milano, Italy
2001 Specialization degree in Hematology. ”Università degli Studi di Milano”, Milano Italy
2002-2006 research contract in Oncology “Università degli studi di Modena” department of Oncology and hematology”, Modena
2006-2015 Assistant Professor, medical Oncology Università degli studi di Modena” department of Oncology and hematology”, Modena
From 11/2015 Associate Professor, medical Oncology, Università degli studi di Modena e Reggio Emilia, Modena

From 12/2015 Head of the “Onco-hematology clinical research program” within the division of Hematology, at the Santa Maria Nuova IRCCS Hospital, Reggio Emilia, Italy.

2003 Visiting assistant Professor at Oncology/Hematology division, Feinberg School of Medicine, Northwestern University, Chicago (IL); USA.
Post-lauream courses
– 2000 “Nineth European tutorial on Hemopathology: Leukemias and Lymphomas”. Organizzato dall European School of Hematology. London 25-29 March 2000. D. Catovsky, G. Flandrin, J. Diebold.
– 2002 Mediterranean School of Oncology course on Malignant Lymphomas. Roma 4-7 March 2002. (Ref. Prof. Stefano Iacobelli). Endorsed by European Society of Medical Oncology (ESMO).
– 2003 CITI 1-Core Course in the protection of Human research Subjects. Biomedical research Modules of the Collaborative IRB training Initiative (CITI), sponsored by the University of Miami (FL), USA. Final exam
on 9/9/2003 with score higher than 70%
– 2012 “Future Advance in Management Expertise (FAME)” SDA Bocconi school of management

Clinical activity:
He heads the “Clinical research program” of the division of Hematology at the Santa Maria Nuova IRCCS
Hospital, Reggio Emilia, His clinical activity is strictly integrated with his teaching and research activity and is
mainly dedicated to the diagnostic, clinical and therapeutic management of patients with lymphoproliferative

Research activities:
1996 al 2001: researcher in the molecular biology laboratory of Experimental Hematology unit of “Ospedale
Maggiore IRCCS, Policlinico di Milano, head by Dr. Antonino Neri
From 2001 to 2010, coordinator of clinical research office of Italian Lymphoma Study Group (GISL),
From 2001 scientific consultant of Modena Cancer registry, in the research area of lymphoproliferative disease and urologic cancers.
During 2003 research experience on pharmacovigilance studies of the RADAR group (Research on Adverse Event and Report) at Northwestern University, Chicago (IL, USA)
– From 2010 coordinator of clinical research programs for the data center of the Fondazione Italiana Linfomi
– From 2001 coinvestigator in several clinical trials and studies on lymphoproliferative diseases in collaboration with italian and international cooperative groups (IELSG, ITCP, IFLPFP).
– From 2010 scientific advisor for research in lymphomas of the Linfocare program at the Reggio Emilia Hematology unit.
Summary of research and clinical interests. Dr. Luminari’s activity is highly focused on clinical research in malignant lymphomas. In particular he is an expert in biomarkers and prognostic studies, in phase II and III
clinical trials, and in population based studies. He is active member of the Fondazione Italiana Linfomi, the most important cooperative group for lymphoma research in Italy, an is chair of the Indolent Lymphoma
scientific subcommittee of the organizazion. His research topics include indolent lymphomas, In particular Follicular Lymphomas, Hodgkin lymphomas, aggressive lymphomas (mainly elderly patients) and the use of
FDG-PET in lymphomas. He has coauthored several studies aimed at investigating the prognostic role of clinical and biological markers. His most important and recent manuscript are the long term update of the
randomized FOLL05 trial (luminari et al. JCO 2018) and the assessment of POD24 in Marginal zone lymphoma (Luminari et al Blood 2019). Of note his contribution in the study of FDG-PET in Follicular Lymphoma in the staging (Luminari et al Ann Oncol 2013) and restaging assessment after induction therapy (Luminari et al. Ann Oncol 2014, Trotman J et al. Lancet Hematol 2014) and in the integration of PET with minimal residual disease for response assessment (Luminari Haematologia 2015). He has an active role in the international observational “T-Cell Project” study and is PI of the IELSG50 phase II trial conducted in China for the treatment of ENKTCL. He is chair of the Lymphoma section of the Associazione Italiana di Oncologia Medica (AIOM) national guidelines since 2019. Finally he isvery active in improving communication and dissemination of scientific results as member of the “Lymphomahub” ( and Lymhphoma connect ( web education platforms and through the use of social media (twitter account @stefanoluminari).

Is author or coauthor of more than 200 publications listed on ISI and/or Scopus. Is author of 159 articles printed on international peer reviewed journals indexed in scopus and of three chapter books. Is first, last or
corresponding author in 30 publications. His H-index (Scopus) is 40. Number of citations as of feb 9, 2020 5440.
2004 G. Luppi Prize (Modena).
2005 ORCA Prize (Optimizing Research in Cacer Anemia) (Nizza, Francia)
2018 Dr Calabresi prize for the best scientific article of 2018 (grandangolo Ematologia Milano november 2018)